Skip Navigation

Masks are required inside all of our care facilities. We are vaccinating all eligible patients. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Email Alerts

Find more COVID-19 testing locations on

Center for Addiction and Pregnancy (CAP) - Research

Director: Denis Antoine, M.D.
Administrative Director:
Dana Madden, LCPC

The Center for Addiction and Pregnancy (CAP) at the Johns Hopkins Bayview Medical Centeris a community-based treatment center located on the campus of The Johns Hopkins Bayview Medical Center.  Since its inception in 1991, CAP has been committed to generating evidence-based research and applying these findings to improve the treatment provided. Given the various disciplines involved in the program (obstetrics, pediatrics and psychiatry), this is an ideal setting for patients to receive comprehensive care.  Research projects conducted at CAP have examined a wide variety of questions including optimal medication and counseling services for pregnant women with substance use disorders, the role of partners in the treatment process for women at the program, the cost and benefit of the services provided, and novel behavioral treatments for pregnant women with active substance use disorders.

Learn about Clinical Services offered by the Center for Addiction and Pregnancy.

Selection of Recent CAP Study Publications

Maternal buprenorphine treatment during pregnancy and maternal physiology. Jansson LM, Velez ML, McConnell K, Milio L, Spencer N, Jones H, DiPietro JA. Drug Alcohol Depend. 2019 Aug 1;201:38-44. doi: 10.1016/j.drugalcdep.2019.03.018. Epub 2019 May 31. PubMed PMID: 31176949.

Neonatal Abstinence Syndrome. Jansson LM, Patrick SW. Pediatr Clin North Am. 2019 Apr;66(2):353-367. doi: 10.1016/j.pcl.2018.12.006. Review. PubMed PMID: 30819342.

The Impact of Early Substance Use Disorder Treatment Response on Treatment Outcomes Among Pregnant Women With Primary Opioid Use.Tuten M, Fitzsimons H, Hochheimer M, Jones HE, Chisolm MS. J Addict Med. 2018 Jul/Aug;12(4):300-307. doi: 10.1097/ADM.0000000000000397. PubMed PMID: 29538089.

Prenatal buprenorphine exposure and neonatal neurobehavioral functioning. Velez ML, McConnell K, Spencer N, Montoya L, Tuten M, Jansson LM. Early Hum Dev. 2018 Feb;117:7-14. doi: 10.1016/j.earlhumdev.2017.11.009. Epub 2017 Dec 7. PubMed PMID: 29223912.

Maternal buprenorphine treatment and infant outcome.Jansson LM, Velez ML, McConnell K, Spencer N, Tuten M, Jones H, Rios R, King VL, Gandotra N, Millio L, DiPietro JA. Drug Alcohol Depend. 2017 Nov 1;180:56-61. doi: 10.1016/j.drugalcdep.2017.08.001. Epub 2017 Aug 31. PubMed PMID: 28869859; PubMed Central PMCID: PMC5788458.

The Effect of Sexual Abuse and Prenatal Substance Use on Successful Breastfeeding.Jansson LM, Velez ML, Butz AM. J Obstet Gynecol Neonatal Nurs. 2017 May - Jun;46(3):480-484. doi: 10.1016/j.jogn.2017.02.002. Epub 2017 Mar 31. Review. PubMed PMID: 28371620.

Maternal buprenorphine treatment and fetal neurobehavioral development. Jansson LM, Velez M, McConnell K, Spencer N, Tuten M, Jones HE, King VL, Gandotra N, Milio LA, Voegtline K, DiPietro JA. Am J Obstet Gynecol. 2017 May;216(5):529.e1-529.e8. doi: 10.1016/j.ajog.2017.01.040. Epub 2017 Feb 7. PubMed PMID: 28188773; PubMed Central PMCID: PMC5420468.

Naltrexone in the treatment of opioid-dependent pregnant women: common ground. Jones HE, Chisolm MS, Jansson LM, Terplan M.  Addiction. 2013 Feb;108(2):255-6. doi: 10.1111/add.12071.

A Comparison of Cigarette Smoking Profiles in Opioid-Dependent Pregnant Patients Receiving Methadone or Buprenorphine.  Chisolm MS, Fitzsimons H, Leoutsakos JM, Acquavita SP, Heil SH, Wilson-Murphy M, Tuten M, Kaltenbach K, Martin PR, Winklbaur B, Jansson LM, Jones HE.  Nicotine Tob Res. Jan 3, 2013.  doi: 10.1093/ntr/nts274

Velez M, Jansson LM.  The substance exposed dyad: Evaluation and intervention in the perinatal period.  Parenting and Substance Addiction: Developmental approaches to intervention.  Suchman NE, Pajulo M, Mayes LC (Eds.) First Edition. Oxford University Press, New York, NY 10016. 2012; In press.

Cigarette smoking in opioid-dependent pregnant women: Neonatal and maternal outcomes.  Jones HE, Heil SH, Tuten M, Chisolm MS, Foster JM, O'Grady KE, Kaltenbach K.  Drug Alcohol Depend. Dec 29, 2012. doi: 10.1016/j.drugalcdep.2012.11.019

Contingent incentives reduce cigarette smoking among pregnant, methadone-maintained women: results of an initial feasibility and efficacy randomized clinical trial.  Tuten M, Fitzsimons H, Chisolm MS, Nuzzo PA, Jones HE.  Addiction. 2012 Oct;107(10):1868-77. doi: 10.1111/j.1360-0443.2012.03923.x.

The efficacy of escalating and fixed contingency management reinforcement on illicit drug use in opioid-dependent pregnant women.  Hutchinson ML, Chisolm MS, Tuten M, Leoutsakos JM, Jones HE.  Addict Disord Their Treat. 2012 Sep;11(3):150-153. PMID: 23226717

Lessons learned from a randomized trial of fixed and escalating contingency management schedules in opioid-dependent pregnant women.  Tuten M, Svikis DS, Keyser-Marcus L, O'Grady KE, Jones HE.  Am J Drug Alcohol Abuse. 2012 Jul;38(4):286-92. doi: 10.3109/00952990.2011.643977.

Neonatal abstinence syndrome.  Jansson LM, Velez M.  Curr Opin Pediatr. 2012 Apr;24(2):252-8. doi: 10.1097/MOP.0b013e32834fdc3a.

 Cigarette Smoking and Neonatal Outcomes in Depressed and Non-Depressed Opioid-Dependent Agonist-Maintained Pregnant Patients.  Chisolm MS, Acquavita SP, Kaltenbach K, Winklbaur B, Heil SH, Martin PR, Stine SM, Coyle M, Leoutsakos JM, Tuten M, Jansson LM, Backer PM, Jones HE.  Addict Disord Their Treat. 2011 Dec;10(4):180-187.

Reinforcement-based treatment improves the maternal treatment and neonatal outcomes of pregnant patients enrolled in comprehensive care treatment.  Jones HE, O'Grady KE, Tuten M.  Am J Addict. 2011 May-Jun;20(3):196-204. doi: 10.1111/j.1521-0391.2011.00119.x.

Treating the partners of opioid-dependent pregnant patients: feasibility and efficacy.  Jones HE, Tuten M, O'Grady KE.  Am J Drug Alcohol Abuse. 2011 May;37(3):170-8. doi: 10.3109/00952990.2011.563336.

HIV Sexual and Drug-Use Risk in Drug-Dependent Pregnant Patients in Comprehensive Drug Treatment.  Jones HE, Wechsberg WM, O'Grady KE, Tuten M.  Int J Family Med. 2011:872638. doi: 10.1155/2011/872638.

Neonatal abstinence syndrome after methadone or buprenorphine exposure.  Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G.  N Engl J Med. 2010 Dec;363(24):2320-31. doi: 10.1056/NEJMoa1005359.

Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center.  Chisolm MS, Brigham EP, Lookatch SJ, Tuten M, Strain EC, Jones HE.  J Subst Abuse Treat. 2010 Oct;39(3):298-305. doi: 10.1016/j.jsat.2010.06.008.

The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse.  Chisolm MS, Brigham EP, Tuten M, Strain EC, Jones HE.  Am J Drug Alcohol Abuse. 2010 Jan;36(1):46-51. doi: 10.3109/00952990903544844.

The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.  Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE.  Am J Drug Alcohol Abuse. 2009;35(5):358-63. doi: 10.1080/00952990903108231. 

back to top button